Protein Expression Profiling and Virtual Drug Screening as an Approach for Individualized Therapy of Small Cell Vaginal Carcinoma

Publication type:
Journal article
Metadata:
Autoren
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000817687300004&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.21873/cgp.20337
eISSN
1790-6245
Externe Identifier
  • Clarivate Analytics Document Solution ID: 2M4RA
  • PubMed Identifier: 35732326
ISSN
1109-6535
Ausgabe der Veröffentlichung
4
Zeitschrift
CANCER GENOMICS & PROTEOMICS
Schlüsselwörter
  • Biomarker
  • chemical carcinogenesis
  • drug repurposing
  • individualized therapy
Paginierung
512 - 525
Datum der Veröffentlichung
2022
Status
Published
Titel
Protein Expression Profiling and Virtual Drug Screening as an Approach for Individualized Therapy of Small Cell Vaginal Carcinoma
Sub types
  • Article
Ausgabe der Zeitschrift
19

Data source: Web of Science (Lite)

Other metadata sources:
Autoren
DOI
10.21873/cgp.20337
eISSN
1790-6245
ISSN
1109-6535
Ausgabe der Veröffentlichung
4
Zeitschrift
Cancer Genomics - Proteomics
Sprache
en
Online publication date
2022
Paginierung
512 - 525
Datum der Veröffentlichung
2022
Status
Published
Herausgeber
Anticancer Research USA Inc.
Herausgeber URL
http://dx.doi.org/10.21873/cgp.20337
Datum der Datenerfassung
2023
Titel
Protein Expression Profiling and Virtual Drug Screening as an Approach for Individualized Therapy of Small Cell Vaginal Carcinoma
Ausgabe der Zeitschrift
19

Data source: Crossref

Abstract
<h4>Background</h4>Small cell vaginal carcinoma is a very rare gynecological cancer and treatments including chemo- and radiotherapy have had limited success.<h4>Case report</h4>We report the case of a 37-year-old female, where intensive treatment with the combination of paclitaxel, carboplatin, irinotecan, and camptothecin with and without irradiation did not avoid metastasis of the tumor and the death of the patient. In an attempt to develop a strategy for individualized tumor therapy, we performed immunohistochemistry of 19 cancer-related proteins using a biopsy sample. Strong expression was observed for glutathione S-transferase P1 (GSTP1), epidermal growth factor receptor (EGFR), inducible nitric oxide synthetase (iNOS), nuclear factor kappa B (NF-κB), the oncogene c-MYC, vascular endothelial growth factor (VEGF), and the proliferation marker Ki-67. Intermediate expression was found for the oncogene SRC, β-catenin, and the viral E7 protein. We then performed virtual drug screening with PyRx and molecular docking with AutoDock 4.2.6 by using the three-dimensional structures of these proteins and a chemical library of 1,577 FDA-approved drugs, in a drug repurposing approach. The top 15 compounds were either approved anticancer drugs or drugs used to treat non-malignant diseases. These compounds were bound with comparable or even higher affinity to the targets compared to control inhibitors. Several of these compounds were bound with high affinity to more than one of these target proteins, further supporting the drug repurposing concept.<h4>Conclusion</h4>These drugs might offer additional opportunities to reach treatment responses. This approach of individualized tumor therapy might be theoretically not only applicable for small cell vaginal carcinoma but for other tumor entities as well.
Addresses
  • Johannes Gutenberg University, Institute of Pharmaceutical and Biomedical Sciences, Mainz, Germany.
Autoren
DOI
10.21873/cgp.20337
eISSN
1790-6245
Externe Identifier
  • PubMed Identifier: 35732326
  • PubMed Central ID: PMC9247883
Open access
false
ISSN
1109-6535
Ausgabe der Veröffentlichung
4
Zeitschrift
Cancer genomics & proteomics
Schlüsselwörter
  • Humans
  • Carcinoma
  • Vascular Endothelial Growth Factor A
  • NF-kappa B
  • Drug Evaluation, Preclinical
  • Adult
  • Female
  • Molecular Docking Simulation
Sprache
eng
Medium
Print
Paginierung
512 - 525
Datum der Veröffentlichung
2022
Status
Published
Datum der Datenerfassung
2022
Titel
Protein Expression Profiling and Virtual Drug Screening as an Approach for Individualized Therapy of Small Cell Vaginal Carcinoma.
Sub types
  • Journal Article
  • Case Reports
  • case-report
Ausgabe der Zeitschrift
19

Files

https://cgp.iiarjournals.org/content/cgp/19/4/512.full.pdf https://europepmc.org/articles/PMC9247883?pdf=render

Data source: Europe PubMed Central

Abstract
BACKGROUND: Small cell vaginal carcinoma is a very rare gynecological cancer and treatments including chemo- and radiotherapy have had limited success. CASE REPORT: We report the case of a 37-year-old female, where intensive treatment with the combination of paclitaxel, carboplatin, irinotecan, and camptothecin with and without irradiation did not avoid metastasis of the tumor and the death of the patient. In an attempt to develop a strategy for individualized tumor therapy, we performed immunohistochemistry of 19 cancer-related proteins using a biopsy sample. Strong expression was observed for glutathione S-transferase P1 (GSTP1), epidermal growth factor receptor (EGFR), inducible nitric oxide synthetase (iNOS), nuclear factor kappa B (NF-κB), the oncogene c-MYC, vascular endothelial growth factor (VEGF), and the proliferation marker Ki-67. Intermediate expression was found for the oncogene SRC, β-catenin, and the viral E7 protein. We then performed virtual drug screening with PyRx and molecular docking with AutoDock 4.2.6 by using the three-dimensional structures of these proteins and a chemical library of 1,577 FDA-approved drugs, in a drug repurposing approach. The top 15 compounds were either approved anticancer drugs or drugs used to treat non-malignant diseases. These compounds were bound with comparable or even higher affinity to the targets compared to control inhibitors. Several of these compounds were bound with high affinity to more than one of these target proteins, further supporting the drug repurposing concept. CONCLUSION: These drugs might offer additional opportunities to reach treatment responses. This approach of individualized tumor therapy might be theoretically not only applicable for small cell vaginal carcinoma but for other tumor entities as well.
Date of acceptance
2022
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/35732326
DOI
10.21873/cgp.20337
eISSN
1790-6245
Externe Identifier
  • PubMed Central ID: PMC9247883
Ausgabe der Veröffentlichung
4
Zeitschrift
Cancer Genomics Proteomics
Schlüsselwörter
  • Biomarker
  • chemical carcinogenesis
  • drug repurposing
  • individualized therapy
  • Adult
  • Carcinoma
  • Drug Evaluation, Preclinical
  • Female
  • Humans
  • Molecular Docking Simulation
  • NF-kappa B
  • Vascular Endothelial Growth Factor A
Sprache
eng
Country
Greece
Paginierung
512 - 525
PII
19/4/512
Datum der Veröffentlichung
2022
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2022
Titel
Protein Expression Profiling and Virtual Drug Screening as an Approach for Individualized Therapy of Small Cell Vaginal Carcinoma.
Sub types
  • Case Reports
  • Journal Article
Ausgabe der Zeitschrift
19

Data source: PubMed

Beziehungen:
Property of

Tools